Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models.

ABSTRACT:

Background

Genetic alteration of the MET receptor tyrosine kinase frequently occurs in glioblastoma (GBM). Clinically, bevacizumab treatment results in MET signaling activation, leading to GBM recurrence with a more malignant phenotype. While MET has been a promising therapeutic target, MET inhibitors have not been successful in treating GBM patients. MET-directed chimeric antigen receptor (CAR) T cells hold the promise of targeting MET-positive GBM regardless of genetic alterations or kinase activity.

Methods

GBM patient-derived xenografts (PDX) harboring MET amplification (MET^amp) or PTPRZ-MET fusion (ZM) were propagated in vivo followed by glioma stem cell (GSC) isolation. Cell-based assays were used for comparing GSC survival in response to MET inhibitors and

SUBMITTER: Qin A 

PROVIDER: S-EPMC12013037 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature